PEDIATRIC NASAL SPRAY SOLUTION: FACTORIAL DESIGN DEVELOPMENT AND EVALUATION
The work was aimed to develope the meter dose formulation of pediatric xylometazoline nasal spray formulation. The 32 factorial design was utilized for development of the pediatric formulation. The independent factors were sodium cholate (X1) and Polyethyleneglycol 400 concentration (X2). The optimized formulation composition consisted of 0.105 g sodium cholate and 1.35 ml polyethyleneglycol 400. The formulation was evaluated for solution parameters like drug content, pH, viscosity, % diffusion, sterility and spray evaluation parameters like spray content uniformity, pump delivery, spray pattern, and weight loss. The results for spray content uniformity were in the range of 95-102 %, while pH in the range of 6.5 ± 0.3. The ovality of spray was 1.118, while perimeter and area of spray pattern were found to be 57.42 mm and 258.8 mm2 respectively for optimized formulation. The least value for repriming was 97.6 % while the extreme value was 102.2 % indicating one actuation was satisfactory for repriming. The results for droplet size test were obtained in the range of 51.63 to 58.90 µm. The formulation along with its container closure was evaluated for its stability up to 12 months at long term conditions. The formulated batch PFE showed better performance for in-vitro drug release with marketed product thus providing another option for treatment of nasal congestion.
2) Cheeda S, Sangale S, Srhate. Advantageous Drug delivery system: A Review. International Journal of Pharmaceutical Sciences and Research. 2011; 2(6):1322-1336.
3) Corbo DC, Liu JC, Chien YW. Characterization of the barrier properties of mucosal membranes. Journal of Pharmaceutical Sciences. 1990; 79:202–206.
4) McMartin C, Hutchinson LE, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. Journal of Pharmaceutical Sciences. 1987; 76:535–540.
5) Karin O, Mattias P, Erik B, Katarina E. Evaluation of drug release from gels on pig nasal mucosa in a horizontal Ussing chamber. Journal of Controlled Release. 2002; 83:377–388.
6) Ivanovska V, Rademaker CMA, L van Dijk, Mantel-Teeuwisse AK. Pediatric drug formulations: A review of challenges and progress: Pediatrics. 2014; 134(2):361-372.
7) Pritchard S, Glover M, Guthrie G, Brum J, Ramsey D, Kappler G, Thomas P, Stuart S, Hull D, Gowland P. Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post-administration by magnetic resonance imaging. Pulmonary Pharmacology and Therapeutics. 2014; 27:121-126.
8) Elizabeth AE, Russell AF, Thomas AE, Platts-Mills, Larry B. Epidemiological analysis of chronic rhinitis in pediatric patients. American Journal of Rhinology and Allergy. 2011; 25(5):327–332.
9) Shuai Qian, Yin Cheong Wong, Zhong Zuo. Development, characterization and application of in situ gel systems for in tranasal delivery of tacrine. International Journal of Pharmaceutics 2014; 468:272–282.
10) Michael S, Ferguson BJ, Len F. Epedemeology and burden of nasal congestion. International Journal of General Medicine 2010; 3:37-45.
11) Menaka M, Pandey VP, Anton Smith A. Formulation development and evaluation of ondansetron hydrochloride nasal spray. International Journal of Pharmacy and Pharmaceutical Sciences 2013; 5(4):150-154.
12) Unites States Pharmacopoeis, Rockville, Maryland, USA. USP – 29 Volume No 28(3) Page 795. USP Monograph of Xylometazoline nasal solution : http://www.pharmacopeia.cn/v29240/usp29nf24s0_m89300.html
13) Indian Pharmacopoeia. Vol. II, 4th edition. The controller of publication, New Delhi; 1996. Page 736.
14) Michael I, Ug woke, Remigius U, Norbert Verbcke. Nasal mucoadhesive drug delivery system; background applications, trends, and future perspectives. Advance drug delivery 2005; 57(11):1641-1660.
15) Menaka M, Pandey VP. Formulation development and evaluation of cinnarizine nasal spray. International Journal of Pharma Researxh and Health Sciences. 2014; 2 (4):339-346.
16) Patil VB, Kalkotwar RS, Patel Ankita, Tathe Swati , Jadhav VB. Evaluation and quality control of nasal spray. Journal of Drug Delivery & Therapeutics. 2012; 2(4):1-4.
17) Guidance for Industry: Nasal spray and inhalation solution, suspension and spray drug products – Chemistry, Manufacturing and Controls; Food and Drug Administration Center for Drug Evaluation and Research (CDER). July 2002: 1-40.
18) Guideline on the pharmaceutical quality of inhalation and nasal Products, EMEA.
19) Swati P, Ganesh R, Ganesh B. Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. European Journal of Pharmaceutical Sciences. 2013; 48:195–201.
20) Shivhare UD, Jain KZB, Mathur VB, Bhusari KP, Roy AA. Formulation development and evaluation of diclofenac sodium gel using water soluble polyacrylamide polymer. Digest Journal of Nanomaterials and Biostructures. 2009; 4(2):285-290.
21) Suria PK, Ramakrishna Ch., Srivani M, Priyanka VN, Y Bindu Priya. Comparative invitro release of diclofenac sodium gel from different marketed products. International Journal of Life Science and Pharma Research. 2012; 2(3):88-93.
22) Swapnil SC and Mohmed HG. Quality by design approach for development of suspension nasal spray products: a case study on budesonide nasal suspension; Drug Development and Industrial Pharmacy. 2016; 42 (10):1643-1652.
23) Unites States Pharmacopoeis, Rockville, Maryland, USA. Microbiological Tests / 〈71〉 Sterility Tests, Page 2508. (http://www.drugfuture.com/Pharmacopoeia/usp35/PDF/0069-074%20%20STERILITY%20TESTS.pdf)
24) Stability testing of New drug substances and products Q1A (R2): February 2003.
25) Eskandar M, Abdulghani A, Somayeh H. Absorption-Enhancing Effects of Bile Salts. Molecules. 2015; 20(8):14451-14473.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).